1287 related articles for article (PubMed ID: 26284719)
1. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
2. Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
Bauersachs R; Lee AYY; Kamphuisen PW; Meyer G; Janas MS; Jarner MF; Khorana AA;
Thromb Haemost; 2018 May; 118(5):914-921. PubMed ID: 29618162
[TBL] [Abstract][Full Text] [Related]
3. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
[TBL] [Abstract][Full Text] [Related]
4. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Hyers TM; Spyropoulos AC;
J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
[TBL] [Abstract][Full Text] [Related]
5. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
Kamphuisen PW; Lee AYY; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
J Thromb Haemost; 2018 Jun; 16(6):1069-1077. PubMed ID: 29573330
[TBL] [Abstract][Full Text] [Related]
6. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
[TBL] [Abstract][Full Text] [Related]
7. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
8. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Fiessinger JN; Huisman MV; Davidson BL; Bounameaux H; Francis CW; Eriksson H; Lundström T; Berkowitz SD; Nyström P; Thorsén M; Ginsberg JS;
JAMA; 2005 Feb; 293(6):681-9. PubMed ID: 15701909
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
Ferro JM; Coutinho JM; Dentali F; Kobayashi A; Alasheev A; Canhão P; Karpov D; Nagel S; Posthuma L; Roriz JM; Caria J; Frässdorf M; Huisman H; Reilly P; Diener HC;
JAMA Neurol; 2019 Dec; 76(12):1457-1465. PubMed ID: 31479105
[TBL] [Abstract][Full Text] [Related]
10. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR;
J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799
[TBL] [Abstract][Full Text] [Related]
11. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
Meyer G; Marjanovic Z; Valcke J; Lorcerie B; Gruel Y; Solal-Celigny P; Le Maignan C; Extra JM; Cottu P; Farge D
Arch Intern Med; 2002 Aug 12-26; 162(15):1729-35. PubMed ID: 12153376
[TBL] [Abstract][Full Text] [Related]
12. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
13. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
15. Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.
Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Anderson JL; Li J; Rodriguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple B; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
JAMA; 2019 Sep; 322(9):834-842. PubMed ID: 31479138
[TBL] [Abstract][Full Text] [Related]
16. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
17. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
[TBL] [Abstract][Full Text] [Related]
18. Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.
Rabe E; Hoffmann U; Schimke A; Heinken A; Langer F; Noppeney T; Pittrow D; Klotsche J; Gerlach HE; Bauersachs R;
Eur J Vasc Endovasc Surg; 2023 Nov; 66(5):697-704. PubMed ID: 37573936
[TBL] [Abstract][Full Text] [Related]
19. Structured benefit-risk assessment for enoxaparin, in the context of its label extension, for the extended treatment of deep vein thrombosis and pulmonary embolism, and prevention of its recurrence in patients with active cancer.
Kürzinger ML; El-Haddad C; Gouin-Soboleva T; Fazekas Z; Granados D; Benito-Garcia E; Djoudi Y
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5795. PubMed ID: 38680090
[TBL] [Abstract][Full Text] [Related]
20. Secondary prevention of venous thromboembolism: A role for low-molecular-weight heparin.
Monreal M; Roncales FJ; Ruiz J; Muchart J; Fraile M; Costa J; Hernandez JA
Haemostasis; 1998; 28(5):236-43. PubMed ID: 10420072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
